VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim
Metrics: PDF 697 views | HTML 1167 views | ?
Nurulhuda Mustafa1, Jeannie Xue Ting Lee2, Huey Fang Adina Nee2, Chonglei Bi1, Tae-Hoon Chung2, Stefan Hart4 and Wee Joo Chng1,2,3
1Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2Cancer Science Institute of Singapore, National University of Singapore, Singapore
3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore
4S*BIO Pte Ltd., Singapore
Wee Joo Chng, email: firstname.lastname@example.org
Keywords: myeloma, dual PI3K/mTOR inhibitor, RARRES3, panobinostat, therapeutics
Received: March 28, 2017 Accepted: September 22, 2017 Published: October 20, 2017
The PI3K/mTOR/AKT pathway is an integral regulator of survival and drug resistance in multiple myeloma (MM). VS-5584 was synthesized with dual-specific and equipotent activity against mTORC1/2 and all four Class I PI3K isoforms so as to durably inhibit this pathway. We show that VS-5584 is highly efficacious against MM cell lines even in the presence of IL-6 and IGF-1 and that this growth inhibition is partially dependent on Bim. Importantly, VS-5584 triggers apoptosis in patient cells with a favorable therapeutic index. Gene expression profiling revealed a VS-5584-induced upregulation of RARRES3, a class II tumor suppressor gene. MM patient databases, UAMS and APEX, show that RARRES3 is under-expressed in 11q13 subsets which correlates with the reduced effectiveness of VS-5584 in 11q13 cell lines. Silencing RARRES3 expression significantly rescues VS-5584-induced cell death and increases cyclin D2 expression but not cyclin D1 or other cyclins implying a role for RARRES3 in cell cycle arrest. In vivo, VS-5584 significantly reduces the tumor burden of MM mouse xenografts. We further identified that VS-5584 synergised with Dexamethasone, Velcade, and exceptionally so with HDAC inhibitor, Panobinostat. Interestingly, this was consistently observed in several patient samples, proposing a promising novel clinical strategy for combination treatment especially in relapsed/refractory patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.